• STAAR Surgical reported past second-quarter 2026 results showing sales of US$93.54 million versus US$44.32 million a year earlier, with net income of US$8.06 million replacing a net loss of US$16.81 million and earnings per share improving to US$0.16 from a US$0.34 loss.

• Alongside these results, the board's recent move to appoint long-time operator Warren Foust as CEO underscores how leadership changes and an operational reset have coincided with the company's shift back to profitability.

• We'll now examine how this sharp swing to profitability and leadership consolidation under Warren Foust may reshape STAAR Surgical's investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

STAAR Surgical Investment Narrative Recap

To own STAAR Surgical, you need to believe its implantable lens business can translate regulatory wins and operational improvements into durable profitability, while managing its China exposure and competitive pressures. The sharp Q2 2026 swing to profit and much higher sales is encouraging, but the key near term catalyst remains execution in China and other growth markets, with the biggest risk still centered on distributor dynamics, demand volatility and inventory overhang in China. The latest results materially sharpen that tension.

The most relevant recent development is Warren Foust's appointment as permanent CEO and board member. He has been closely involved in STAAR's operational reset and return to profitability, which now provides a clearer leadership anchor around the improving Q1 and Q2 2026 earnings. For investors, the question is how this leadership continuity will influence product rollout decisions, capital allocation and the company's ability to balance growth investments against cost discipline across its key regions.

Yet behind the strong Q2 numbers, investors should be aware of how heavily STAAR still relies on a single product category and what happens if that market...

Read the full narrative on STAAR Surgical (it's free!)

STAAR Surgical's narrative projects $400.0 million revenue and $36.5 million earnings by 2029. This requires 11.3% yearly revenue growth and a $57.5 million earnings increase from -$21.0 million today.

Uncover how STAAR Surgical's forecasts yield a $29.67 fair value , a 13% upside to its current price.